Asset Details
Do you wish to reserve the book?
Histopathologic image–based deep learning classifier for predicting platinum-based treatment responses in high-grade serous ovarian cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Histopathologic image–based deep learning classifier for predicting platinum-based treatment responses in high-grade serous ovarian cancer
Do you wish to request the book?
Histopathologic image–based deep learning classifier for predicting platinum-based treatment responses in high-grade serous ovarian cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Histopathologic image–based deep learning classifier for predicting platinum-based treatment responses in high-grade serous ovarian cancer
2024
Overview
Platinum-based chemotherapy is the cornerstone treatment for female high-grade serous ovarian carcinoma (HGSOC), but choosing an appropriate treatment for patients hinges on their responsiveness to it. Currently, no available biomarkers can promptly predict responses to platinum-based treatment. Therefore, we developed the Pathologic Risk Classifier for HGSOC (PathoRiCH), a histopathologic image–based classifier. PathoRiCH was trained on an in-house cohort (
n
= 394) and validated on two independent external cohorts (
n
= 284 and
n
= 136). The PathoRiCH-predicted favorable and poor response groups show significantly different platinum-free intervals in all three cohorts. Combining PathoRiCH with molecular biomarkers provides an even more powerful tool for the risk stratification of patients. The decisions of PathoRiCH are explained through visualization and a transcriptomic analysis, which bolster the reliability of our model’s decisions. PathoRiCH exhibits better predictive performance than current molecular biomarkers. PathoRiCH will provide a solid foundation for developing an innovative tool to transform the current diagnostic pipeline for HGSOC.
Predicting the response to platinum-based chemotherapy in high-grade serous ovarian carcinoma (HGSOC) remains challenging. Here, the authors develop the histopathology image-based Pathologic Risk Classifier for HGSOC - PathoRiCH - to predict and stratify HGSOC patient response to therapy, especially when combined with molecular biomarkers.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Adult
/ Aged
/ Biomarkers, Tumor - genetics
/ Biomarkers, Tumor - metabolism
/ Cancer
/ Cystadenocarcinoma, Serous - diagnostic imaging
/ Cystadenocarcinoma, Serous - drug therapy
/ Cystadenocarcinoma, Serous - genetics
/ Cystadenocarcinoma, Serous - pathology
/ Female
/ Humanities and Social Sciences
/ Humans
/ Ovarian Neoplasms - diagnostic imaging
/ Ovarian Neoplasms - drug therapy
/ Ovarian Neoplasms - genetics
/ Ovarian Neoplasms - pathology
/ Platinum
/ Risk
/ Science
